Should I buy Manhattan Associates (MANH) stock or is it too late?

Manhattan Associates · Information Technology · price $223

See the full Manhattan Associates (MANH) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stifel — 69% of its targets hit on this sector (209 calls tested). It aims for $225 (+1.0 %), call made on July 30, 2026, maturing on July 30, 2027 (76 d ago).

The 5 reliable analysts $215-3.5 %

The 2 other firms $245+9.8 %

How to read it: the 5 reliable firms are not filtered by optimism — 2 aim above the price, 3 below, hence their $215 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Manhattan Associates

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Rosenblatt	80 %	+37.5 %	10	$150 -33%
Raymond James	58 %	+10.5 %	12	$240 +8%
Loop Capital	50 %	+4.5 %	6	$215 -3%
Baird	25 %	-8.1 %	8	$260 +17%
Truist Securities	30 %	-10.9 %	10	$240 +8%
DA Davidson	0 %	-22.1 %	9	$210 -6%
Benchmark	83 %	+46.6 %	6	—
SunTrust Robinson Humphrey	83 %	+42.5 %	6	—

In short — Should you invest in Manhattan Associates? Is it too late, still worth it? Analysts are overwhelmingly positive (86% buy, median target $225, i.e. +1%), and the most reliable on MANH targets even higher. But the stock is volatile, it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

86% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
The most reliable firm on MANH, Raymond James (58% hit rate, 12 scored calls), targets $240 (call made on October 22, 2025, maturing on October 22, 2026) (+8%) in its most recent call.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 1 is neutral.
Limited upside: the median target is only +1% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Volatile stock: sharp swings — including steep drops — are part of its profile.
No dividend: your return depends only on price appreciation.

The analyst consensus on MANH

Median target $225 (+1%) · 7 ratings · Buy consensus

Strong Buy00%

Buy686%

Hold114%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Manhattan Associates now?

We won't decide for you. The facts: 86% of analysts rate it a buy, median target $225 (+1%), and Raymond James (most reliable on MANH, 58%) targets $240. Weigh that against valuation and volatility. This is not personalized advice.

Is it too late to invest in Manhattan Associates?

The stated upside is small: the median target ($225) sits just +1% from the price ($223) (most reliable on MANH: Raymond James, 58%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Manhattan Associates still worth investing in?

It depends on the gap between the price ($223) and its estimated value: analysts target $225 on median (+1%), with 86% buys (most reliable on MANH: Raymond James, 58%). Cross-check with their real reliability on MANH and the cautions above. Information, not advice.

What's the main risk in buying MANH?

The consensus is not unanimous: of 7 ratings, 1 is neutral.

→ Go deeper: the full Manhattan Associates profile (consensus, analyst reliability, price target, performance).